B

Beijing SL Pharmaceutical Co Ltd
SZSE:002038

Watchlist Manager
Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Watchlist
Price: 8.45 CNY -0.47% Market Closed
Updated: May 17, 2024

Beijing SL Pharmaceutical Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Beijing SL Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
B
Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Net Income (Common)
¥284.9m
CAGR 3-Years
-10%
CAGR 5-Years
-14%
CAGR 10-Years
-7%
Beigene Ltd
HKEX:6160
Net Income (Common)
-¥6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Income (Common)
-¥1B
CAGR 3-Years
-1%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
¥1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
¥7.5B
CAGR 3-Years
26%
CAGR 5-Years
35%
CAGR 10-Years
50%
Imeik Technology Development Co Ltd
SZSE:300896
Net Income (Common)
¥1.3B
CAGR 3-Years
61%
CAGR 5-Years
73%
CAGR 10-Years
N/A

See Also

What is Beijing SL Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
284.9m CNY

Based on the financial report for Mar 31, 2024, Beijing SL Pharmaceutical Co Ltd's Net Income (Common) amounts to 284.9m CNY.

What is Beijing SL Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-7%

Over the last year, the Net Income (Common) growth was -24%. The average annual Net Income (Common) growth rates for Beijing SL Pharmaceutical Co Ltd have been -10% over the past three years , -14% over the past five years , and -7% over the past ten years .